IMPACT OF ORAL FLEROXACIN ON THE FECAL FLORA OF HEALTHY VOLUNTEERS

• Published in: CHEMOTHERAPY Vol. 38; no. Supplement2; pp. 328 - 337
• Main Authors: WATANABE, KUNITOMO, KATOH, NAOKI, MUTO, YOSHINORI, BANDOH, KAORI, SAWA, KAKUYO, UENO, KAZUE
• Format: Journal Article
• Language: Japanese
• Published: Japanese Society of Chemotherapy 1990
• Subjects: Fleroxacin
• ISSN: 0009-3165; 1884-5894
• DOI: 10.11250/chemotherapy1953.38.Supplement2_328

Fleroxacin is a newly developed quinolone derivative, with a broad spectrum of activity against Gram-negative and-positive bacteria, including aerobes and anaerobes. It has the longest serum half-life of all the new quinolones. Fecal flora were studied in five healthy adult male volunteers after the administration of 400mg fleroxacin b.i.d. for seven days. Stool samples were taken prior to and several times after the initiation of therapy, and qualitative and quantitative analyses of microorganisms were performed. Enterobacteriaceae were eliminated in all volunteers by the end of therapy. No resistant Enterobacteriaceae were observed. The number of CFU of the Bacteroides fragilis group remained unchanged or changed only slightly during the trial. There was no selective growth of Clostridium difficile and resistant B. fragilis group organisms.